Literature DB >> 11694248

Measurement of growth hormone, insulin-like growth factor I and their binding proteins: the clinical aspects.

K C Leung1, K K Ho.   

Abstract

BACKGROUND: Growth hormone (GH) secreted from the pituitary stimulates the production of insulin-like growth factor I (IGF-I) from the liver and extrahepatic tissues, which in turn regulates tissue proliferation and differentiation in an endocrine or autocrine/paracrine manner. Both GH and IGF-I circulates as complexes with specific binding proteins. The GH binding protein (GHBP) corresponds to the extracellular, ligand-binding domain of the GH receptors in tissues and its serum concentration may reflect the status of the tissue receptors. Most serum IGF-I associates with IGF binding protein 3 (IGFBP-3) and another protein, the acid labile subunit (ALS). Like IGF-I, serum concentrations of IGFBP-3 and ALS are tightly regulated by GH. GH secretion (both spontaneous and stimulated), IGF-I, IGFBP-3, and ALS have been assessed as potential biochemical markers for diagnosis of GH-related disorders.
CONCLUSIONS: In acromegaly, IGF-I is the most reliable marker. The peak GH response to insulin tolerance test is the diagnostic test of choice, GH deficiency. GHBP has no diagnostic value in acromegaly or GH deficiency. However, it may be a potential biochemical marker for GH insensitivity syndrome as serum GHBP concentrations are undetectable or reduced in >75% of these patients. Other biochemical tests may also prove to be useful in these disorders, but require further validation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11694248     DOI: 10.1016/s0009-8981(01)00662-3

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  6 in total

Review 1.  Metabolic actions of insulin-like growth factor-I in normal physiology and diabetes.

Authors:  David R Clemmons
Journal:  Endocrinol Metab Clin North Am       Date:  2012-06       Impact factor: 4.741

2.  VeloceGenomics: an accelerated in vivo drug discovery approach to rapidly predict the biologic, drug-like activity of compounds, proteins, or genes.

Authors:  Ruben Papoian; Andreas Scherer; Muriel Saulnier; Frank Staedtler; André Cordier; Francois Legay; Gerard Maurer; Joerg Staeheli; Jacky Vonderscher; Salah-Dine Chibout
Journal:  Pharm Res       Date:  2005-09-22       Impact factor: 4.200

Review 3.  The GH/IGF-1 system in critical illness.

Authors:  Itoro E Elijah; Ludwik K Branski; Celeste C Finnerty; David N Herndon
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2011-10       Impact factor: 4.690

4.  Pediatric reference intervals for FSH, LH, estradiol, T3, free T3, cortisol, and growth hormone on the DPC IMMULITE 1000.

Authors:  Offie P Soldin; Eve G Hoffman; Michael A Waring; Steven J Soldin
Journal:  Clin Chim Acta       Date:  2005-05       Impact factor: 3.786

5.  Gamma-Aminobutyric Acid (GABA) Promotes Growth in Zebrafish Larvae by Inducing IGF-1 Expression via GABAA and GABAB Receptors.

Authors:  Athapaththu Mudiyanselage Gihan Kavinda Athapaththu; Ilandarage Menu Neelaka Molagoda; Rajapaksha Gedara Prasad Tharanga Jayasooriya; Yung Hyun Choi; You-Jin Jeon; Joung-Hyun Park; Bae-Jin Lee; Gi-Young Kim
Journal:  Int J Mol Sci       Date:  2021-10-19       Impact factor: 5.923

Review 6.  Mass spectrometry-based approaches to targeted quantitative proteomics in cardiovascular disease.

Authors:  Clementina Mesaros; Ian A Blair
Journal:  Clin Proteomics       Date:  2016-10-05       Impact factor: 3.988

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.